First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer: a cost-effectiveness analysis from China

BACKGROUND: IMpower 133 trial first confirmed the efficacy and safety of adding atezolizumab or placebo to first-line treatment with chemotherapy in patients with extensive-stage small-cell lung cancer (SCLC). While, overprice limited its broad use in clinical. The aim of this study was to evaluate...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ling-Yu, Wang, Hong, Chen, Xiao, Li, Wen-Qian, Cui, Jiu-Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940079/
https://www.ncbi.nlm.nih.gov/pubmed/31856049
http://dx.doi.org/10.1097/CM9.0000000000000536

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940079/
https://www.ncbi.nlm.nih.gov/pubmed/31856049
http://dx.doi.org/10.1097/CM9.0000000000000536

Ejemplares similares